Drugs for Hypopharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 126)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Dopamine |
Approved |
Phase 4,Phase 2 |
|
51-61-6, 62-31-7 |
681
|
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
2 |
|
Bupropion |
Approved |
Phase 4,Phase 2 |
|
34841-39-9, 34911-55-2 |
444
|
Synonyms:
( -)-2-(tert-Butylamino)-3'-chloropropiophenone
( -)-2-(tert-Butylamino)-3'-chlorpropiophenon
(+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-Bupropion
.alpha.-(tert-Butylamino)-m-chloropropiophenone
1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
2-(Tert-Butylamino)-3'-chloropropiophenone
34841-36-6 (hydrochloride)
34841-39-9
34911-55-2
AB00053756
AC-197
AC1L198Y
alpha-(tert-butylamino)-m-chloropropiophenone
Amfebutamon
Amfebutamona
Amfebutamona [INN-Spanish]
Amfebutamone
AMFEBUTAMONE HCl
amfebutamonum
Amfebutamonum
Amfebutamonum [INN-Latin]
BPBio1_000042
BRD-A05186015-003-05-7
BRN 2101062
BSPBio_000038
BSPBio_002247
bupropion
Bupropion (INN)
Bupropion (Old RN)
Bupropion (USAN)
Bupropion [INN:BAN]
Bupropion Hcl
Bupropion hydrochloride
Bupropion hydrochloride, (+-)-isomer
Bupropion hydrocloride
Bupropion SR
Bupropion, (+-)-isomer
C06860
CHEBI:3219
CHEMBL894
CID444
CPD000472526
D07591
DB01156
DivK1c_007050
Elont
|
Esteve brand OF bupropion hydrochloride
glaxo Wellcome brand 1 OF bupropion hydrochloride
glaxo Wellcome brand 2 OF bupropion hydrochloride
glaxo Wellcome brand 3 OF bupropion hydrochloride
GlaxoSmithKline brand 1 OF bupropion hydrochloride
GlaxoSmithKline brand 2 OF bupropion hydrochloride
HMS2051G10
HMS2089G14
Jsp006301
KBio1_001994
KBio2_002143
KBio2_004711
KBio2_007279
KBio3_001467
KBioGR_001168
KBioSS_002143
L000725
Lopac0_000166
LS-122817
MLS001424015
MolPort-003-845-432
NCGC00015122-06
NCGC00089751-02
NCI60_002714
NSC315851
Prestwick0_000249
Prestwick1_000249
Prestwick2_000249
Prestwick3_000249
Quomen
SAM001246699
SMR000472526
SPBio_001817
SPBio_002257
SpecPlus_000954
Spectrum_001663
Spectrum2_001659
Spectrum3_000644
Spectrum4_000614
Spectrum5_001406
TL8002604
UNII-01ZG3TPX31
Wellbatrin
Wellbutrin
Wellbutrin SR
Wellbutrin XL
Zyban
Zyban (anti-smoking)
Zyntabac
|
|
3 |
|
Nicotine |
Approved |
Phase 4,Not Applicable |
|
54-11-5 |
942
89594
|
Synonyms:
(−
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-methylpyrrolidino)Pyridine
(−)-nicotine
(-)-Nicotine
(-)-Nicotine solution
(+)-Nicotine
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(−)-nicotine
(S)-(-)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(1-Methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-Methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridal)-pyrrolidine
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(2-(N-Methylpyrrolidinyl))pyridine
3-(N-methylpyrollidino)pyridine
3-(N-methylpyrollidino)Pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-methylpyrrolidino)Pyridine
3-(N-Methylpyrrolidino)pyridine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
3-N-Methylpyrrolidine
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
a -N-Methylpyrrolidine
AC1L3I79
AC1Q3ZOC
AI3-03424
alpha-N-Methylpyrrolidine
a-N-Methylpyrrolidine
BB_NC-0777
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
BIDD:GT0599
Bitartrate, nicotine
Black Leaf
Black Leaf 40
bmse000105
BRD-K05395900-322-02-1
C00745
Campbell's Nico-Soap
Caswell No. 597
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
Commit
CPD000059074
D03365
delta-Nicotine
Destruxol
Destruxol Orchid Spray
DL-Tetrahydronicotyrine
D-Nicotine
EINECS 200-193-3
Emo-Nik
ENT 3,424
EPA Pesticide Chemical Code 056702
Flux Maag
fumeto Bac
Fumetobac
|
Habitrol
Habitrol (TN)
HSDB 1107
L(-)-nicotine
L(−)-nicotine
L(-)-Nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
L-Nicotine
LS-202
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MLS001055457
MLS001335905
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
Niagara P.A. Dust
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nico-Dust
Nico-Fume
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
nicotine
Nicotine
Nicotine (compounds related to)
Nicotine (USP)
Nicotine [BSI:ISO]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotine Alkaloid
NICOTINE AND SALTS
Nicotine betadex
Nicotine bitartrate
Nicotine Patch
Nicotine polacrilex
Nicotine Polacrilex
nicotine replacement patch
Nicotine tartrate
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nic-Sal
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
NSC 5065
NSC97238
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tartrate, nicotine
Tendust
Transdermal Nicotine
UN1654
|
|
4 |
|
Liver Extracts |
|
Phase 4,Phase 2,Not Applicable |
|
|
|
5 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 4,Phase 2 |
|
|
|
6 |
|
Antidepressive Agents |
|
Phase 4,Phase 2 |
|
|
|
7 |
|
Antidepressive Agents, Second-Generation |
|
Phase 4,Phase 2 |
|
|
|
8 |
|
Dopamine Uptake Inhibitors |
|
Phase 4,Phase 2 |
|
|
|
9 |
|
Neurotransmitter Uptake Inhibitors |
|
Phase 4,Phase 2 |
|
|
|
10 |
|
Psychotropic Drugs |
|
Phase 4,Phase 2 |
|
|
|
11 |
|
Dopamine Agents |
|
Phase 4,Phase 2 |
|
|
|
12 |
|
Cytochrome P-450 CYP2D6 Inhibitors |
|
Phase 4,Phase 2 |
|
|
|
13 |
|
Neurotransmitter Agents |
|
Phase 4,Phase 2,Phase 3,Not Applicable |
|
|
|
14 |
|
Peripheral Nervous System Agents |
|
Phase 4,Phase 2,Phase 3,Not Applicable |
|
|
|
15 |
|
Nicotinic Agonists |
|
Phase 4,Not Applicable |
|
|
|
16 |
|
Cholinergic Agents |
|
Phase 4,Phase 2,Phase 3,Not Applicable |
|
|
|
17 |
|
Autonomic Agents |
|
Phase 4,Phase 2,Phase 3,Not Applicable |
|
|
|
18 |
|
Central Nervous System Stimulants |
|
Phase 4,Not Applicable |
|
|
|
19 |
|
Fluorouracil |
Approved |
Phase 3,Phase 2,Phase 1 |
|
51-21-8 |
3385
|
Synonyms:
1004-03-1
1-fluoro-1h-pyrimidine-2,4-dione
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 Fluorouracil
5 Fluorouracil biosyn
5 FU lederle
5 FU Lederle
5 FU medac
5 HU hexal
5 HU Hexal
51-21-8
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-fluoropyrimidine-2,4(1H,3H)-dione
5-Fluoropyrimidine-2,4-dione
5-fluorouracil
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5FU
5-FU
5-FU (TN)
5-FU lederle
5-FU Lederle
5-FU medac
5-HU hexal
5-HU Hexal
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
AI3-25297
AKOS000119162
AKOS003237897
Allergan brand OF fluorouracil
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
biosyn Brand of Fluorouracil
Biosyn brand OF fluorouracil
BSPBio_002048
C07649
C4H3FN2O2
Carac
Carac (TN)
Carzonal
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
Cinco FU
CPD000038082
CPD0-1327
CSP Brand of Fluorouracil
CSP Brand OF fluorouracil
Cytosafe
D005472
D00584
Dakota brand OF fluorouracil
Dakota Brand of Fluorouracil
Dakota, fluorouracile
Dakota, Fluorouracile
DB00544
Dermatech brand OF fluorouracil
Dermatech Brand of Fluorouracil
Dermik brand OF fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
EINECS 200-085-6
EU-0100536
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
Ferrer brand OF fluorouracil
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
fluoro Uracile icn
Fluoro Uracile ICN
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
fluorouracil
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil [USAN:INN:BAN:JAN]
Fluorouracil gry
Fluorouracil GRY
Fluorouracil mononitrate
Fluorouracil Mononitrate
Fluorouracil monopotassium salt
Fluorouracil Monopotassium Salt
Fluorouracil monosodium salt
Fluorouracil Monosodium Salt
Fluorouracil potassium salt
Fluorouracil Potassium Salt
Fluorouracil teva brand
Fluorouracil Teva Brand
Fluorouracile
Fluoro-uracile
Fluorouracile [DCIT]
|
Fluorouracile dakota
Fluorouracile Dakota
fluoro-Uracile icn
Fluoro-Uracile ICN
Fluorouracil-gry
Fluorouracil-GRY
Fluorouracilo
Fluoro-uracilo
Fluorouracilo [INN-Spanish]
fluorouracilo Ferrer far
Fluorouracilo Ferrer Far
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
FT-0082524
Ftoruracil
FU
Gry brand OF fluorouracil
Gry Brand of Fluorouracil
haemato Brand OF fluorouracil
Haemato Brand of Fluorouracil
haemato Fu
Haemato fu
haemato-Fu
Haemato-fu
Hexal brand OF fluorouracil
Hexal Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
I07-0022
ICN brand OF fluorouracil
ICN Brand of Fluorouracil
IDI1_000054
IN1335
inhibits thymilidate synthetase
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
Lopac0_000536
Lopac-F-6627
LS-153
medac Brand of Fluorouracil
Medac brand OF fluorouracil
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
nchembio.90-comp3
nchembio809-comp6
NCI60_001652
Neocorp brand OF fluorouracil
Neocorp Brand of Fluorouracil
Neofluor
NINDS_000054
NSC 19893
NSC19893
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Onkoworks Brand of Fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
ribosepharm Brand of Fluorouracil
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche brand OF fluorouracil
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
Spectrum_000841
SPECTRUM1500305
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
STK297802
T5233394
tetratogen
Teva brand OF fluorouracil
Teva Brand of Fluorouracil
Timazin
TL8006093
U 8953
U-8953
Ulup
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
WLN: T6MVMVJ EF
ZINC00897110
|
|
20 |
|
Cisplatin |
Approved |
Phase 3,Phase 2,Phase 1 |
|
15663-27-1 |
2767
441203
84093
|
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatine
cisplatino
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
CPDC
|
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
21 |
|
Docetaxel |
Approved, Investigational |
Phase 3,Phase 2,Phase 1 |
|
114977-28-5 |
148124
|
Synonyms:
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
01885_FLUKA
114977-28-5
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC1L3WHJ
AC-383
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
docetaxel
Docetaxel
Docetaxel (INN)
docetaxel 114977-28-5
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxel, Trihydrate
Docetaxol
|
EmDOC
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
Taxoltere metro
Taxotere
Taxotere (TN)
Taxotere(R)
TXL
XRP-6976L
|
|
22 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178
38904
498142
|
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
Blastocarb
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
Carboplat
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Carbosin
Carbotec
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
|
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
Nealorin
Neocarbo
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Ribocarbo
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
23 |
|
Pilocarpine |
Approved, Investigational |
Phase 2, Phase 3 |
|
54-71-7, 92-13-7 |
5910
|
Synonyms:
(+)-Pilocarpine
(3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one
(3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
(3S,4R)-3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S,4R)-3-ethyldihydro-4-((1-Methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S,4R)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S-cis)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone
(3S-cis)-3-ethyldihydro-4-[(1-Methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone
(3S-cis)-3-Ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone
3-ethyl-4-((1-methyl-1H-imidazol-5-yl)methyl)dihydro-2(3H)-furanone
3-Ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)dihydrofuran-2-one
3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydro-2(3H)-furanone
3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one
3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
54-71-7
91484-73-0
92-13-7
AC1L1J0W
AC1L1LEF
AC1Q6MOP
Adsorbocarpine
AI3-50523
Almocarpine
Amistura P
AR-1F3128
beta-Pilocarpine hydrochloride
BIDD:GT0217
BPBio1_000548
BRD-K85090592-008-05-2
BSPBio_000498
BSPBio_002191
C07474
CHEBI:39460
CHEBI:8207
CHEMBL550
CID4819
CID5910
D00525
DB01085
DivK1c_000358
EINECS 202-128-4
Epicar
HMS2089K17
HSDB 3163
Hydrochloride, pilocarpine
IDI1_000358
Imidazole-5-butyric acid, alpha-ethyl-beta-(hydroxymethyl)-1-methyl-, gamma-lactone
isopilocarpine
Isopilocarpine
Isopto carpine
Isoptocarpine
KBio1_000358
KBio2_001587
KBio2_004155
KBio2_006723
KBio3_001691
KBioGR_000956
KBioSS_001587
L001181
Lopac0_000950
Lopac0_000960
LS-187208
LS-7661
Minims Pilocarpine
Miocarpine
Mi-Pilo
MolPort-002-512-506
|
NCGC00023339-03
NCGC00023339-06
NCGC00023339-07
NCGC00023339-08
NCGC00023339-09
NCGC00023339-12
NCGC00023339-13
nchembio.78-comp9
NCI60_004403
NINDS_000358
Nitrate, pilocarpine
NSC5746
Ocu-Carpine
Ocusert
Ocusert P 20
Ocusert pilo
Ocusert pilo-20
Ocusert pilo-20 (TN)
Ocusert Pilo-40
P.V. Carpine Liquifilm
Pilagan
Pilocarpin
pilocarpine
Pilocarpine
Pilocarpine (JAN/USP)
Pilocarpine [USAN:BAN:JAN]
Pilocarpine chloride
Pilocarpine HCl
Pilocarpine HCL
Pilocarpine hydrochloride
Pilocarpine monohydrochloride
Pilocarpine mononitrate, (3S-cis)-isomer
Pilocarpine Mononitrate, (3S-cis)-Isomer
Pilocarpine muriate
Pilocarpine nitrate
Pilocarpine, monohydrochloride, (3S-cis)-isomer
Pilocarpine, Monohydrochloride, (3S-cis)-Isomer
Pilocarpol
Pilokarpin
Pilokarpin monohydrochloride
Pilokarpol
Piloptic-1
Piloptic-1/2
Piloptic-2
Piloptic-3
Piloptic-4
Piloptic-6
Pilostat
Prestwick0_000449
Prestwick1_000449
Prestwick2_000449
Prestwick3_000449
Salagen
SDCCGMLS-0003164.P005
SPBio_001287
SPBio_002437
Spectrum_001107
Spectrum2_001284
Spectrum3_000546
Spectrum4_000478
Spectrum5_001379
Spersacarpine
Spersacarpine hydrochloride
STOCK1N-18408
Syncarpine
Tocris-0694
UNII-01MI4Q9DI3
ZINC00075008
|
|
24 |
|
Kava |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
9000-38-8 |
|
25 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
26 |
|
Antimitotic Agents |
|
Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
27 |
|
Antimetabolites, Antineoplastic |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
28 |
|
Immunosuppressive Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
29 |
|
Immunologic Factors |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
30 |
|
Antimetabolites |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
31 |
|
Muscarinic Agonists |
|
Phase 2, Phase 3 |
|
|
|
32 |
|
Immunoglobulins |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
33 |
|
Antibodies |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
34 |
|
Amifostine |
Approved, Investigational |
Phase 2,Phase 1 |
|
20537-88-6 |
2141
|
Synonyms:
Alza brand OF amifostine
Amifostina
Amifostine alza brand
Amifostine anhydrous
Amifostine disodium salt
Amifostine essex brand
Amifostine ethiofos
Amifostine lilly brand
Amifostine monohydrate
Amifostine monohydrochloride
Amifostine schering-plough brand
Amifostine trihydrate
Amifostinum
Aminopropyl aminoethylthiophosphate
Aminopropylaminoethyl thiophosphate
Aminopropylaminoethylthiophosphate
Aminopropylaminoethylthiophosphoric acid
Anhydrous, amifostine
|
Anhydrous, ethiofos
Apaetp
Disodium salt, amifostine
Essex brand OF amifostine
Ethiofos
Ethiofos anhydrous
Ethyol
Gammaphos
Lilly brand OF amifostine
Monohydrate, amifostine
Monohydrochloride, amifostine
S-(N-(3-Aminopropyl)-2-aminoethyl)thiophosphoric acid
SAPEP
Schering plough brand OF amifostine
Schering-plough brand OF amifostine
Trihydrate, amifostine
US bioscience brand OF amifostine
WR-1065
|
|
35 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 1, Phase 2,Phase 2,Not Applicable |
|
33069-62-4 |
36314
|
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-epi-Paclitaxel
7-Epipaclitaxel
7-Epi-paclitaxel
7-epi-Taxol
7-Epitaxol
7-Epi-taxol
AB00513812
ABI 007
abi-007
ABI007
ABI-007
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
AC1L1IOG
AC1L1VJI
AC1L9AVF
AC-675
ACon1_002231
albumin-bound paclitaxel
Ambotz33069-62-4
ANX-513
Anzatax
Asotax
BIDD:PXR0046
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
Bris taxol
Bristaxol
BSPBio_000290
BSPBio_001152
BSPBio_002614
C07394
C466458
C47H51NO14
Capxol
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
cMAP_000068
CPD-8718
D00491
DB01229
DHP-107
DHP-208
DivK1c_000441
DRG-0190
DTS-301
Ebetaxel
EmPAC
Epitaxol
EU-0101201
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
|
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LipoPac
LMPR0104390001
Lopac0_001201
LS-31070
MBT 0206
MEGxp0_001940
Micellar Paclitaxel
Mitotax
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
MPI-5018
nab-paclitaxel
Nanotaxel
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
NCI60_000601
Neuro_000060
NINDS_000441
NK 105
Nova-12005
NP-010981
NSC 125973
NSC125973
NSC-125973
NSC358882
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
paclitaxel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S1150_Selleck
S-8184 Paclitaxel Injectable Emulsion
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
Spectrum_001536
SPECTRUM1503908
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
ST50306996
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TaxAlbin
Taxol
TAXOL
TAXOL (TN)
Taxol a
Taxol A
Taxol Konzentrat
TAXOL, 10-EPI,
Taxol, bris
Taxol.RTM. (Registered Trademark)
TXL
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
weekly paclitaxel
Xorane
Yewtaxan
|
|
36 |
|
Gemcitabine |
Approved |
Phase 1, Phase 2 |
|
95058-81-4 |
60750
|
Synonyms:
103882-84-4
122111-03-9
2',2'-DFDC
2',2'-DiF-dC
2',2'-difluoro-2'-Deoxycytidine
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-Hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFdC
DFDC
DFdCyd
Folfugem
Gamcitabine
Gemcel
Gemcin
Gemcitabin
|
Gemcitabina
Gemcitabina [INN-Spanish]
gemcitabine
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
GemLip
Gemtro
Gemzar
Gemzar (hydrochloride)
GEO
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY188011
LY-188011
NCGC00168784-01
NChemBio.2007.10-comp25
nchembio.573-comp7
nchembio.90-comp2
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
Zefei
ZINC18279854
|
|
37 |
|
Ritonavir |
Approved, Investigational |
Phase 2 |
|
155213-67-5 |
392622
|
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
538, ABT
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
A-84538
Abbott 84538
ABBOTT-84538
ABT 538
ABT 84538
ABT538
ABT-538
AC1L94GB
AC-733
AKOS000280930
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
DB00503
|
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
NSC693184
RIT
ritonavir
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
RTV
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
|
|
38 |
|
Indinavir |
Approved |
Phase 2 |
|
150378-17-9 |
5362440
|
Synonyms:
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
150378-17-9
157810-81-6
157810-81-6 (sulfate (1:1) (salt))
166746-42-5
1c6y
1hsg
1hsh
1k6c
1sdt
1sdu
1sdv
1sgu
216884-06-9
2avo
2avs
2avv
2bpx
AC1L1U7I
AC-20034
AKOS000280989
BIDD:GT0378
BIDD:PXR0141
C07051
C36H47N5O4
CHEBI:44032
|
Compound J
Crixivan
Crixivan (TM)
DB00224
IDV
indinavir
Indinavir (*1:1 Sulfate salt*)
Indinavir [USAN]
Indinavir anhydrous
Indinavir sulfate
Indinavir sulphate
Indinavir, sulfate (1:1)
Indinavir, Sulfate (1:1)
L 735524
L-735 524
L-735,524
L-735524
LS-173382
MK-639
MolPort-000-883-804
N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE
NCGC00159460-02
NSC697197
Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
Propolis+Indinavir
RS-253
Sulfate, indinavir
UNII-9MG78X43ZT
|
|
39 |
|
Cetuximab |
Approved |
Phase 2 |
|
205923-56-4 |
56842117
2333
|
Synonyms:
205923-56-4
Anti EGFR
cetuximab
Cetuximab
Cétuximab
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
|
Cetuximab (USAN/INN)
Cetuximabum
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
|
|
40 |
|
Hydroxyurea |
Approved |
Phase 1, Phase 2,Phase 2 |
|
127-07-1 |
3657
|
Synonyms:
127-07-1
1-HYDROXYUREA
4-03-00-00170 (Beilstein Handbook Reference)
55291_FLUKA
AC1L1GF8
AC1Q4ZXK
AI3-51139
BB_SC-7256
Bio1_000451
Bio1_000940
Bio1_001429
Biosupressin
BRN 1741548
BSPBio_002164
C07044
carbamide oxide
Carbamohydroxamate
Carbamohydroxamic acid
Carbamohydroxamic Acid
Carbamohydroximate
Carbamohydroximic acid
Carbamohydroximic Acid
Carbamohydroxyamic acid
Carbamohydroxyamic Acid
Carbamoyl oxime
Carbamoyl Oxime
Carbamyl hydroxamate
Carbamyl Hydroxamate
Carbamyl hydroxamic acid
Carrbamoyl Oxime
CCRIS 958
CHEBI:44423
CHEMBL467
CID3657
D00341
D006918
DB01005
DivK1c_000556
DRG-0253
Droxia
Droxia (TM)
Droxia (TN)
E0723DBA-5AF3-49D1-B5F6-59420AB87AC9
EINECS 204-821-7
EU-0100596
FT-0083575
H 8627
H0310
H20210
H8627_SIGMA
Hidrix
Hidroxicarbamida
Hidroxicarbamida [INN-Spanish]
HMS1920F09
HMS2091L17
HMS501L18
HSDB 6887
HU
Hydrea
Hydrea (TM)
HYDREA (TN)
Hydrea, Biosupressin, Cytodrox, Hydroxyurea
Hydreia
Hydroxicarbamidum
hydroxyaminomethanamide
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamide (JAN/INN)
Hydroxycarbamidum
Hydroxycarbamidum [INN-Latin]
Hydroxycarbamine
Hydroxyharnstoff
Hydroxyharnstoff [German]
Hydroxylurea
hydroxyurea
Hydroxyurea
HYDROXY-UREA
Hydroxyurea (D4)
|
Hydroxyurea (USP)
Hydroxyurea [USAN:BAN]
Hydroxyurea(d4)
Hydura
Hydurea
I05-0250
IDI1_000556
Idrossicarbamide
Idrossicarbamide [Dcit]
Idrossicarbamide [DCIT]
KBio1_000556
KBio2_001389
KBio2_003957
KBio2_006525
KBio3_001384
KBioGR_000383
KBioSS_001389
Litaler
Litalir
Lopac0_000596
Lopac-H-8627
LS-709
MLS001332381
MLS001332382
MLS002153389
MolMap_000029
MolPort-000-003-971
Mylocel
N-(Aminocarbonyl) Hydroxyamine
N-Carbamoylhydroxylamine
NCGC00015520-01
NCGC00015520-02
NCGC00015520-07
NCGC00093974-01
NCGC00093974-02
NCGC00093974-03
NCGC00093974-04
NCGC00093974-05
nchembio.573-comp3
nchembio.90-comp4
nchembio749-comp3
NCI C04831
NCI60_002773
NCI-C04831
NCIMech_000139
NHY
N-HYDROXY UREA
N-Hydroxymocovina
N-Hydroxymocovina [Czech]
N-Hydroxyurea
N-HYDROXYUREA
NINDS_000556
NSC 32065
NSC32065
Oncocarbide
Onco-carbide
Onco-Carbide
Oxyurea
S1896_Selleck
Siklos
SK 22591
SMR000059149
SPBio_000247
Spectrum_000909
SPECTRUM1500344
Spectrum2_000064
Spectrum3_000462
Spectrum4_000012
Spectrum5_000836
S-phase/G-1 interface inhibitor
SQ 1089
SQ-1089
Sterile Urea
tetratogen: inhibits ribonucleoside diphosphate reductase
TL8000673
UNII-X6Q56QN5QC
Ureaphil
WLN: ZVMQ
|
|
41 |
|
Raspberry |
Approved |
Phase 1, Phase 2 |
|
|
|
42 |
|
Trioxsalen |
Approved |
Phase 2 |
|
3902-71-4 |
5585
|
Synonyms:
2',4,8-Trimethylpsoralen
2,5,9-Trimethyl-7H-furo(3,2-g)benzopyran-7-one
4,5',8-Trimethylpsoralen
4,8,5'-Trimethylpsoralen
6-Hydroxy-b,2,7-trimethyl-5-benzofuranacrylate, delta-lactone
6-Hydroxy-b,2,7-trimethyl-5-benzofuranacrylate, δ-lactone
6-Hydroxy-b,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone
6-Hydroxy-b,2,7-trimethyl-5-benzofuranacrylic acid, δ-lactone
6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylate, delta-lactone
6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone
6-Hydroxy-β,2,7-trimethyl-5-benzofuranacrylate, δ-lactone
6-Hydroxy-β,2,7-trimethyl-5-benzofuranacrylic acid, δ-lactone
|
ICN brand OF trioxsalen
trimethylpsoralen
Trimethylpsoralen
Trioxisaleno
Trioxisalenum
Trioxsalen
trioxysalen
Trioxysalen
Trioxysalene
Trioxysalenum
trisoralen
Trisoralen
|
|
43 |
|
Celecoxib |
Approved, Investigational |
Phase 2 |
|
169590-42-5 |
2662
|
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC1L1E6K
AC-4228
AI-525
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
celecoxib
Celecoxib
Célécoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
cMAP_000027
CPD000550473
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
|
KBio2_000912
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
Medicoxib
MLS001165684
MLS001195656
MLS001304708
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC58635
SC-58635
SMR000550473
Solexa
SPBio_001512
Spectrum_000432
SPECTRUM1503678
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM177
YM-177
ZINC02570895
|
|
44 |
|
Zinc |
Approved, Investigational |
Phase 2 |
|
7440-66-6 |
|
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
|
Mannosidase b, alpha
Neutral alpha mannosidase
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
45 |
|
Zinc oxide |
Approved |
Phase 2 |
|
1314-13-2 |
|
Synonyms:
óxido de cinc
oxyde de zinc
Zinc (as oxide)
Zinc (as zinc oxide)
|
Zinc white
Zinci oxydum
Zincum oxydatum
Zinkoxid
|
|
46 |
|
Pregabalin |
Approved, Illicit, Investigational |
Phase 2 |
|
148553-50-8 |
5486971
|
Synonyms:
(3S)-3-(aminomethyl)-5-methylhexanoic acid
(R-)-3-isobutyl GABA
(R-)-3-Isobutyl gaba
(S)-3-(aminomethyl)-5-methylhexanoic acid
(S)-3-(Aminomethyl)-5-methylhexanoic acid
(S)-3-Isobutyl gaba
(S+)-3-isobutyl gaba
(S+)-3-isobutyl GABA
121GE001
148553-50-8
3 Isobutyl gaba
3-(Aminomethyl)-5-methylhexanoic acid
3-isobutyl GABA
3-Isobutyl gaba
AC-1158
AC1NUP03
AKOS005145504
C080245
C8H17NO2
CHEBI:236161
CHEMBL1059
CI 1008
CI-1008
|
CID5486971
D02716
DB00230
FT-0080911
GABA, 3-isobutyl
HSDB 7530
LS-75191
Lyrica
Lyrica (TN)
MolPort-000-861-733
PD 144723
PD-144723
Pregabalin
Pregabalin (JAN/USAN/INN)
Pregabalin [USAN]
Pregablin
S-(+)-3-isobutylgaba
S1731_Selleck
SBB062901
TL8001062
TOS-BB-0910
UNII-55JG375S6M
|
|
47 |
|
Pembrolizumab |
Approved |
Phase 2,Phase 1 |
|
1374853-91-4 |
|
Synonyms:
|
48 |
|
Eniluracil |
Investigational |
Phase 1, Phase 2 |
|
59989-18-3 |
|
Synonyms:
5-ethynyl-2,4(1H,3H)-Pyrimidinedione
5-Ethynyluracil
|
|
|
49 |
|
Radiation-Protective Agents |
|
Phase 2,Phase 1 |
|
|
|
50 |
|
Protective Agents |
|
Phase 2,Phase 1 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 84)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking |
Completed |
NCT00666978
|
Phase 4 |
bupropion hydrochloride |
2 |
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking |
Completed |
NCT00365508
|
Phase 4 |
nicotine lozenge;nicotine patch |
3 |
Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia |
Unknown status |
NCT00081029
|
Phase 3 |
|
4 |
Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer |
Unknown status |
NCT00022373
|
Phase 3 |
iseganan HCl oral solution |
5 |
Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma |
Completed |
NCT00169182
|
Phase 3 |
DOCETAXEL |
6 |
Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC |
Completed |
NCT00162708
|
Phase 2, Phase 3 |
CDDP, 5 Fu |
7 |
Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC |
Completed |
NCT00158652
|
Phase 3 |
5FU, Paraplatin |
8 |
Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer |
Completed |
NCT00008398
|
Phase 3 |
|
9 |
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer |
Completed |
NCT00656513
|
Phase 2, Phase 3 |
Pilocarpine |
10 |
Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection |
Recruiting |
NCT02918955
|
Phase 3 |
Chemotherapy (Cisplatin) |
11 |
IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC |
Active, not recruiting |
NCT00158678
|
Phase 3 |
concomitant cisplatin |
12 |
Concurrent Chemoradiation Versus Surgery With Adjuvant Therapy in Advanced Laryngopharyngeal Cancers |
Terminated |
NCT00128817
|
Phase 3 |
|
13 |
Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer |
Terminated |
NCT01066741
|
Phase 3 |
Homeodent®;1.4% Sodium Bicarbonate solution |
14 |
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence |
Withdrawn |
NCT01142414
|
Phase 3 |
cisplatin;fluorouracil |
15 |
Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer |
Unknown status |
NCT01516996
|
Phase 2 |
docetaxel and cisplatin |
16 |
Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN) |
Unknown status |
NCT01312350
|
Phase 2 |
neoadjuvant docetaxel/cisplatin/fluorouracil;No treatment before definitive CCRT |
17 |
Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer |
Unknown status |
NCT00003777
|
Phase 2 |
amifostine trihydrate;cisplatin;fluorouracil |
18 |
Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer |
Unknown status |
NCT00003251
|
Phase 1, Phase 2 |
amifostine trihydrate;cisplatin;paclitaxel |
19 |
Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck |
Unknown status |
NCT00003182
|
Phase 1, Phase 2 |
cisplatin;gemcitabine hydrochloride |
20 |
Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer |
Unknown status |
NCT00003327
|
Phase 2 |
paclitaxel |
21 |
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases |
Unknown status |
NCT00637637
|
Phase 2 |
indinavir sulfate;ritonavir |
22 |
Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation |
Completed |
NCT00169247
|
Phase 2 |
cetuximab;Cisplatin |
23 |
Swallowing Intervention During Radiochemotherapy on Head and Neck Cancer |
Completed |
NCT02075385
|
Phase 2 |
|
24 |
Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx |
Completed |
NCT00243113
|
Phase 2 |
docetaxel |
25 |
A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx |
Completed |
NCT02055989
|
Phase 1, Phase 2 |
|
26 |
A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab |
Completed |
NCT01435252
|
Phase 2 |
Cetuximab |
27 |
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer |
Completed |
NCT00833261
|
Phase 2 |
cetuximab;cisplatin |
28 |
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer |
Completed |
NCT00004901
|
Phase 1, Phase 2 |
ethynyluracil;fluorouracil;hydroxyurea |
29 |
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. |
Completed |
NCT01469429
|
Phase 1, Phase 2 |
chemoprevention;chemoprevention |
30 |
Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer |
Completed |
NCT00002964
|
Phase 2 |
porfimer sodium |
31 |
Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia |
Completed |
NCT00101335
|
Phase 2 |
celecoxib |
32 |
Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer |
Completed |
NCT00002951
|
Phase 2 |
fluorouracil;hydroxyurea |
33 |
Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract |
Completed |
NCT00524017
|
Phase 2 |
|
34 |
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia |
Completed |
NCT00052611
|
Phase 2 |
Celecoxib |
35 |
Bupropion in Helping Adults Stop Smoking |
Completed |
NCT00534001
|
Phase 2 |
bupropion hydrochloride |
36 |
Zinc Supplements in Lowering Cadmium Levels in Smokers |
Completed |
NCT00376987
|
Phase 2 |
|
37 |
New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma |
Recruiting |
NCT03558035
|
Phase 2 |
Induction CT+ CRT group |
38 |
Dose Escalation Versus Standard in Laryngopharyngeal Cancers |
Recruiting |
NCT02757222
|
Phase 1, Phase 2 |
|
39 |
Interest of Pregabalin (Lyrica) on the Treatment of Reflex Earache in Head and Neck Cancer. |
Recruiting |
NCT02924675
|
Phase 2 |
Pregabalin;Placebo |
40 |
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma |
Recruiting |
NCT03082534
|
Phase 2 |
Pembrolizumab, Cetuximab |
41 |
Adaptive Radiotherapy for Head and Neck Cancer |
Recruiting |
NCT03096808
|
Phase 2 |
|
42 |
18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy |
Active, not recruiting |
NCT01806675
|
Phase 1, Phase 2 |
fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide |
43 |
Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer |
Terminated |
NCT00003489
|
Phase 2 |
Antineoplaston therapy (Atengenal + Astugenal) |
44 |
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer |
Unknown status |
NCT00004097
|
Phase 1 |
fluorouracil;gemcitabine hydrochloride;paclitaxel |
45 |
Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors |
Unknown status |
NCT00978081
|
Phase 1 |
aminolevulinic acid hydrochloride |
46 |
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors |
Completed |
NCT01172028
|
Phase 1 |
Taxotere (Docetaxel);Alimta (Pemetrexed) |
47 |
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer |
Completed |
NCT00036790
|
Phase 1 |
doxorubicin hydrochloride;motexafin gadolinium |
48 |
L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors |
Completed |
NCT00003430
|
Phase 1 |
L-778,123 |
49 |
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck |
Completed |
NCT00005647
|
Phase 1 |
paclitaxel;semaxanib |
50 |
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck |
Active, not recruiting |
NCT02113878
|
Phase 1 |
BKM120;Cisplatin |
|